Literature DB >> 7588941

Three-dimensional visualisation of the large bowel: a potential tool for assessing targeted drug delivery and colonic pathology.

A C Perkins1, C Mann, C G Wilson.   

Abstract

A study has been undertaken to assess the feasibility of three-dimensional imaging of the dispersion of a non-absorbable tracer released into the colon of normal subjects. Six healthy volunteers were selected who were participating in a scintigraphic study designed to assess the spreading of 1 MBq indium-111 Amberlite resin delivered from a delayed capsule system targeted to release in the ascending colon. In each case subjects were imaged using a rotating gamma camera over a data collection period of approximately 20 min. Three-dimensional volume rendered images demonstrated good visualisation of the dispersion of the tracer throughout the ascending, transverse and descending colon and provided good anatomical visualisation of the shape of the colon, not previously apparent from the planar views. The present study demonstrates for the first time, the successful three-dimensional imaging of a radiolabelled tracer dispersed throughout the colon and opens up the prospects for more detailed study of quantification of the volume and distribution of tracers contained within the colon.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588941     DOI: 10.1007/BF00808416

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  9 in total

Review 1.  Three-dimensional display in nuclear medicine and radiology.

Authors:  J W Wallis; T R Miller
Journal:  J Nucl Med       Date:  1991-03       Impact factor: 10.057

2.  Three-dimensional display of data obtained by single photon emission computed tomography.

Authors:  S Webb; R J Ott; M A Flower; V R McCready; S Meller
Journal:  Br J Radiol       Date:  1987-06       Impact factor: 3.039

Review 3.  Abdominal SPECT imaging.

Authors:  R L Van Heertum; J C Brunetti; A P Yudd
Journal:  Semin Nucl Med       Date:  1987-07       Impact factor: 4.446

4.  Planar, SPET and three-dimensional immunoscintigraphy of suspected recurrent colorectal cancer using 111In-B72.3 (Oncoscint CR-OV): effect of administered activity.

Authors:  A C Perkins; R M Vincent; M L Wastie; G W Denton; S Amar; J D Hardcastle
Journal:  Nucl Med Commun       Date:  1994-12       Impact factor: 1.690

Review 5.  Radiopharmaceuticals and the gastrointestinal tract.

Authors:  M Frier; A C Perkins
Journal:  Eur J Nucl Med       Date:  1994-11

6.  Noninvasive measurement of human ascending colon volume.

Authors:  A D Badley; M Camilleri; M K O'Connor
Journal:  Nucl Med Commun       Date:  1993-06       Impact factor: 1.690

7.  Validity of the geometric mean correction in the quantification of whole bowel transit.

Authors:  J G Hardy; A C Perkins
Journal:  Nucl Med Commun       Date:  1985-04       Impact factor: 1.690

8.  A technique for the absolute quantification of 131I radiopharmaceuticals using SPECT.

Authors:  J S Fleming; A A Alaamer; S Perring
Journal:  Nucl Med Commun       Date:  1993-06       Impact factor: 1.690

9.  Shape preserving three-dimensional display of myocardial scintigraphic data.

Authors:  A Loboguerrero; C Pérault; C Gibold; J Ouzan; T Pron; A Bouchard; A Lepailleur; J C Liehn
Journal:  Nucl Med Commun       Date:  1994-06       Impact factor: 1.690

  9 in total
  3 in total

Review 1.  Nuclear medicine techniques in the evaluation of pharmaceutical formulations.

Authors:  A C Perkins; M Frier
Journal:  Pharm World Sci       Date:  1996-06

2.  Hydrophilic and lipophilic radiopharmaceuticals as tracers in pharmaceutical development: in vitro--in vivo studies.

Authors:  Mariella Terán; Eduardo Savio; Andrea Paolino; Malcolm Frier
Journal:  BMC Nucl Med       Date:  2005-10-18

3.  Fasting and postprandial volumes of the undisturbed colon: normal values and changes in diarrhea-predominant irritable bowel syndrome measured using serial MRI.

Authors:  S E Pritchard; L Marciani; K C Garsed; C L Hoad; W Thongborisute; E Roberts; P A Gowland; R C Spiller
Journal:  Neurogastroenterol Motil       Date:  2013-10-17       Impact factor: 3.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.